
Five-year KEYNOTE-942 data show a personalized cancer vaccine plus Keytruda reduced recurrence risk in patients with high-risk melanoma.

Five-year KEYNOTE-942 data show a personalized cancer vaccine plus Keytruda reduced recurrence risk in patients with high-risk melanoma.

Mariska Hargitay discusses her father's myeloma, hope from research and the importance of community and caregivers for patients.

Monjuvi and Revlimid plus R-CHOP helped patients with high-risk diffuse large B-cell lymphoma stay in remission longer and reduce relapse risk.

Trodelvy plus Keytruda extended benefit beyond progression in PD-L1-positive metastatic triple-negative breast cancer.

Dr. John Marshall answers common questions about colorectal cancer, including biomarker testing, treatment options, second opinions and more.

A uterine cancer survivor shares her journey through severe bleeding, emergency surgery, daily radiation treatments, and managing post-chemo GI issues.

A survivor shares her personal journey with stage 2A breast cancer, from choosing a bilateral mastectomy to navigating chemotherapy and hair loss.

A 26-year story of survival: Overcoming myelofibrosis, finding a match for a bone marrow transplant, and enduring severe GVHD to help others.

Learn the answers to common questions about bladder cancer, including symptoms, risk factors, stages, BCG therapy, side effects and treatment options.

MosunPola improved progression-free survival and response rates over R-GemOx in transplant-ineligible relapsed large B-cell lymphoma.

Appeals, peer-to-peer reviews and external reviews often overturn insurance denials, helping patients access recommended cancer care.

ONS study shows education improved oncology nurses' confidence discussing medical cannabis, helping reduce stigma and support safer care.

A breast cancer survivor honors her brother’s legacy 50 years after his death by updating her donor registry status to support vital cancer research.

Nurse-led ONS study identifies strategies to reduce CLABSI risk in hematologic cancer care through standardized workflows and documentation.

Investigational bispecific antibody pumitamig achieved a 70% response rate and disease control in all evaluable patients with advanced NSCLC.

ASCO 2026 highlighted advances in pancreatic, breast, sarcoma, lung and prostate cancers that may reshape treatment.

A breast cancer survivor shares the discovery of a new kidney mass and details how she will be a smarter, more assertive patient if it is cancer.

Teen cancer survivor Brynn and friend Teddy created Soothe Note, a free app helping patients track symptoms and prepare for appointments.

FDA approved Cavhanza, a new nilotinib formulation for adults with Ph+ CML that may offer more flexible dosing and easier administration.

Iza-bren improved survival and delayed disease progression versus chemotherapy in previously treated metastatic triple-negative breast cancer.

A Lynch syndrome survivor shares essential prep tips, the importance of stomach cancer screening and how a mindset shift beats yearly scanxiety.

In a phase 3 study, Opdivo plus Yervoy did not improve overall survival when combined with chemotherapy for HER2-negative gastric or GEJ cancer.

Dr. John Marshall explains why biomarker testing should be done early in colorectal cancer to guide treatment and identify targeted therapies.

Kassiane Saieed explains how genomic tools provide data to help patients personalize their breast cancer treatment and survivorship.

Exercise after colon cancer chemotherapy reduced recurrence risk, improved survival and quality of life, according to the CHALLENGE trial.

Press Release
Triage Cancer's Beyond Diagnosis program provides free webinars, guidance, and support for parents living with metastatic cancer.

I thought I understood breast cancer, until a routine conversation at the pharmacy changed everything.

ASCO 2026: Telephone-based weight loss significantly improves physical function and mental health in patients with breast cancer patients who are overweight or obese.

A blood cancer survivor debunks the movie myth of a quick cure, exposing the harsh, lasting side effects that remain after ringing the bell.

Ivonescimab plus chemotherapy helped patients with advanced squamous NSCLC live longer than tislelizumab plus chemotherapy.